BofA analyst Adam Ron downgraded Oscar Health (OSCR) to Underperform from Neutral with a price target of $13.50, down from $21.
BofA analyst Adam Ron downgraded Oscar Health (OSCR) to Underperform from Neutral with a price target of $13.50, down from $21.